Crossmark

Simultaneous Quantitative Analysis of Clarithromycin and Ranitidine, Probe Inhibitors of P-Glycoprotein and OCT1, to Evaluate Potential Pharmacokinetic Influence of Potential Transporter Substrates

Crossref DOI link: https://doi.org/10.1007/s10337-019-03809-7

Published Online: 2019-09-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Scheuch, Eberhard

Abebe, Bayew Tsega

Siegmund, Werner
License Information

Text and Data Mining valid from 2019-09-26

Version of Record valid from 2019-09-26
More Information

Article History

Received: 2 July 2019

Revised: 16 September 2019

Accepted: 17 September 2019

First Online: 26 September 2019

Compliance with Ethical Standards

:

: The authors declare that they have no conflict of interest.

: The clinical study in healthy subjects was performed according to the ICH-guideline for Good Clinical Practice (ICH-GCP), and to the regulations of the German Medicines Act after being approved by the Independent Ethics Committee of the University of Greifswald, the German Federal Department of Drugs and Medicinal Products (BfArM), and after registration by eudract.emea.eu.int (identifier: EudraCT 2016-002882-69) and ClinicalTrials.gov (identifier: NCT03011463). All healthy subjects were included into the study after giving written informed consent. This work was supported by an institutional grant for the Department of Clinical Pharmacology, University Medicine Greifswald from the Dr. R. Pfleger GmbH, Bamberg.

Document is current

Any future updates will be listed below